home / stock / imrx / imrx quote
Last: | $1.13 |
---|---|
Change Percent: | 3.67% |
Open: | $1.1 |
Close: | $1.09 |
High: | $1.15 |
Low: | $1.09 |
Volume: | 16,212 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.13 | $1.1 | $1.09 | $1.15 | $1.09 | 16,212 | 07-03-2024 |
$1.09 | $1.18 | $1.09 | $1.19 | $1.05 | 590,043 | 07-02-2024 |
$1.17 | $1.34 | $1.17 | $1.34 | $1.17 | 354,198 | 07-01-2024 |
$1.28 | $1.44 | $1.28 | $1.44 | $1.28 | 2,510,640 | 06-28-2024 |
$1.43 | $1.39 | $1.43 | $1.435 | $1.32 | 177,852 | 06-27-2024 |
$1.38 | $1.41 | $1.38 | $1.44 | $1.36 | 161,515 | 06-26-2024 |
$1.43 | $1.49 | $1.43 | $1.49 | $1.38 | 263,469 | 06-25-2024 |
$1.49 | $1.43 | $1.49 | $1.55 | $1.43 | 132,905 | 06-24-2024 |
$1.43 | $1.38 | $1.43 | $1.455 | $1.38 | 147,798 | 06-21-2024 |
$1.41 | $1.49 | $1.41 | $1.5 | $1.38 | 141,474 | 06-20-2024 |
$1.48 | $1.54 | $1.48 | $1.55 | $1.43 | 158,186 | 06-19-2024 |
$1.48 | $1.54 | $1.48 | $1.55 | $1.43 | 158,186 | 06-18-2024 |
$1.535 | $1.49 | $1.535 | $1.65 | $1.49 | 415,271 | 06-17-2024 |
$1.51 | $1.65 | $1.51 | $1.67 | $1.475 | 242,963 | 06-14-2024 |
$1.69 | $1.57 | $1.69 | $1.73 | $1.56 | 250,669 | 06-13-2024 |
$1.54 | $1.74 | $1.54 | $1.7932 | $1.5 | 249,381 | 06-12-2024 |
$1.69 | $1.46 | $1.69 | $2.01 | $1.4116 | 768,076 | 06-11-2024 |
$1.49 | $1.36 | $1.49 | $1.5 | $1.3 | 327,023 | 06-10-2024 |
$1.37 | $1.39 | $1.37 | $1.4 | $1.32 | 147,254 | 06-07-2024 |
$1.41 | $1.37 | $1.41 | $1.42 | $1.35 | 100,682 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Immuneering Corporation Company Name:
IMRX Stock Symbol:
NASDAQ Market:
Immuneering Corporation Website:
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies...
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - ...
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of...